Gonadotropin-releasing hormone type II (GnRH-II) agonist regulates the invasiveness of endometrial cancer cells through the GnRH-I receptor and mitogen-activated protein kinase (MAPK)-dependent activation of matrix metalloproteinase (MMP)-2

BMC Cancer

Volumn 13, Issue , 2013, Pages

  Wu, Hsien Ming ^a   Wang, Hsin Shih ^a   Huang, Hong Yuan ^a   Lai, Chyong Huey ^a   Lee, Chyi Long ^a   Soong, Yung Kuei ^a   Leung, Peter C K ^b  

^a CHANG GUNG UNIVERSITY   (Taiwan)

^b UNIVERSITY OF BRITISH COLUMBIA   (Canada)

Author keywords

ERK1 2; GnRH II agonist; Invasion; JNK; MMP 2

Indexed keywords

1,4 DIAMINO 1,4 BIS(2 AMINOPHENYLTHIO) 2,3 DICYANOBUTADIENE; ANTHRA[1,9 CD]PYRAZOL 6(2H) ONE; GELATINASE A; GONADORELIN AGONIST; GONADORELIN RECEPTOR; GONADOTROPIN RELEASING HORMONE I RECEPTOR; GONADOTROPIN RELEASING HORMONE TYPE II AGONIST; MITOGEN ACTIVATED PROTEIN KINASE; MITOGEN ACTIVATED PROTEIN KINASE 1; SMALL INTERFERING RNA; STRESS ACTIVATED PROTEIN KINASE; UNCLASSIFIED DRUG;

ARTICLE; CANCER CELL; CELL ASSAY; CELL INVASION; CELL MIGRATION; CELL MOTILITY; CONCENTRATION RESPONSE; CONTROLLED STUDY; CULTURE MEDIUM; DRUG MECHANISM; DRUG TARGETING; ENDOMETRIUM CANCER; ENZYME ACTIVATION; ENZYME ACTIVITY; ENZYME INHIBITION; ENZYME PHOSPHORYLATION; GENE SILENCING; HUMAN; HUMAN CELL; HUMAN TISSUE; IMMUNOBLOTTING; IMMUNOHISTOCHEMISTRY; PROTEIN EXPRESSION; TUMOR INVASION; ZYMOGRAPHY;

ANTHRACENES; BUTADIENES; CARCINOMA; CELL LINE, TUMOR; CELL MOVEMENT; ENDOMETRIAL NEOPLASMS; ENZYME ACTIVATION; FEMALE; GENE KNOCKDOWN TECHNIQUES; GONADOTROPIN-RELEASING HORMONE; HUMANS; HYDROXAMIC ACIDS; MAP KINASE SIGNALING SYSTEM; MATRIX METALLOPROTEINASE 2; MITOGEN-ACTIVATED PROTEIN KINASES; NEOPLASM INVASIVENESS; NITRILES; PHOSPHORYLATION; RECEPTORS, LHRH;

EID: 84879113865     PISSN: None     EISSN: 14712407     Source Type: Journal    
DOI: 10.1186/1471-2407-13-300     Document Type: Article

References (42)

1. Jemal A, Siegel R, Ward E, Hao Y, Xu J, Murray T, Thun MJ. Cancer statistics, 2008. CA Cancer J Clin 2008, 58:71-96. 10.3322/CA.2007.0010, 18287387.
2. Thoeny HC, Forstner R, De Keyzer F. Genitourinary applications of diffusion-weighted MR imaging in the pelvis. Radiology 2012, 263:326-342. 10.1148/radiol.12110446, 22517953.
3. Kong A, Johnson N, Kitchener HC, Lawrie TA. Adjuvant radiotherapy for stage I endometrial cancer. Cochrane Database Syst Rev 2012, 4. CD003916.
4. Guinot JL, Perez-Calatayud J, Azcoaga JM, Herruzo I, Bodineau C, Rovirosa A, Crispin V, Galan P, Gonzalez-Patino E, Perez-Regadera J, Polo A. Consensus on treatment of endometrium carcinoma with brachytherapy. Clin Transl Oncol 2012, 14:263-270. 10.1007/s12094-012-0794-2, 22484633.
5. Amant F, Moerman P, Neven P, Timmerman D, Van Limbergen E, Vergote I. Endometrial cancer. Lancet 2005, 366:491-505. 10.1016/S0140-6736(05)67063-8, 16084259.
6. Wu HM, Wang HS, Huang HY, Soong YK, MacCalman CD, Leung PC. GnRH signaling in intrauterine tissues. Reproduction 2009, 137:769-777. 10.1530/REP-08-0397, 19208750.
7. Leung PC, Choi JH. Endocrine signaling in ovarian surface epithelium and cancer. Hum Reprod Update 2007, 13:143-162.
8. Ramakrishnappa N, Rajamahendran R, Lin YM, Leung PC. GnRH in non-hypothalamic reproductive tissues. Anim Reprod Sci 2005, 88:95-113. 10.1016/j.anireprosci.2005.05.009, 15982835.
9. Cheng CK, Leung PC. Molecular biology of gonadotropin-releasing hormone (GnRH)-I, GnRH-II, and their receptors in humans. Endocr Rev 2005, 26:283-306.
10. Wu HM, Cheng JC, Wang HS, Huang HY, MacCalman CD, Leung PC. Gonadotropin-releasing hormone type II induces apoptosis of human endometrial cancer cells by activating GADD45alpha. Cancer Res 2009, 69:4202-4208. 10.1158/0008-5472.CAN-08-4591, 19366794.
11. Davidson B, Konstantinovsky S, Kleinberg L, Nguyen MT, Bassarova A, Kvalheim G, Nesland JM, Reich R. The mitogen-activated protein kinases (MAPK) p38 and JNK are markers of tumor progression in breast carcinoma. Gynecol Oncol 2006, 102:453-461. 10.1016/j.ygyno.2006.01.034, 16494928.
12. Kraus S, Naor Z, Seger R. Intracellular signaling pathways mediated by the gonadotropin-releasing hormone (GnRH) receptor. Arch Med Res 2001, 32:499-509. 10.1016/S0188-4409(01)00331-9, 11750725.
13. Kim KY, Choi KC, Park SH, Auersperg N, Leung PC. Extracellular signal-regulated protein kinase, but not c-Jun N-terminal kinase, is activated by type II gonadotropin-releasing hormone involved in the inhibition of ovarian cancer cell proliferation. J Clin Endocrinol Metab 2005, 90:1670-1677.
14. Crespo P, Xu N, Simonds WF, Gutkind JS. Ras-dependent activation of MAP kinase pathway mediated by G-protein beta gamma subunits. Nature 1994, 369:418-420. 10.1038/369418a0, 8196770.
15. Ohmichi M, Sawada T, Kanda Y, Koike K, Hirota K, Miyake A, Saltiel AR. Thyrotropin-releasing hormone stimulates MAP kinase activity in GH3 cells by divergent pathways. Evidence of a role for early tyrosine phosphorylation. J Biol Chem 1994, 269:3783-3788.
16. Bauvois B. New facets of matrix metalloproteinases MMP-2 and MMP-9 as cell surface transducers: outside-in signaling and relationship to tumor progression. Biochim Biophys Acta 1825, 2012:29-36.
17. Sato H, Takino T. Coordinate action of membrane-type matrix metalloproteinase-1 (MT1-MMP) and MMP-2 enhances pericellular proteolysis and invasion. Cancer Sci 2010, 101:843-847. 10.1111/j.1349-7006.2010.01498.x, 20148894.
18. Cheung LW, Leung PC, Wong AS. Gonadotropin-releasing hormone promotes ovarian cancer cell invasiveness through c-Jun NH2-terminal kinase-mediated activation of matrix metalloproteinase (MMP)-2 and MMP-9. Cancer Res 2006, 66:10902-10910. 10.1158/0008-5472.CAN-06-2217, 17108127.
19. Liotta LA, Stetler-Stevenson WG. Tumor invasion and metastasis: an imbalance of positive and negative regulation. Cancer Res 1991, 51:5054s-5059s.
20. Maudsley S, Davidson L, Pawson AJ, Chan R, Lopez de Maturana R, Millar RP. Gonadotropin-releasing hormone (GnRH) antagonists promote proapoptotic signaling in peripheral reproductive tumor cells by activating a Galphai-coupling state of the type I GnRH receptor. Cancer Res 2004, 64:7533-7544. 10.1158/0008-5472.CAN-04-1360, 15492280.
21. Stojilkovic SS, Catt KJ. Expression and signal transduction pathways of gonadotropin-releasing hormone receptors. Recent Prog Horm Res 1995, 50:161-205.
22. Grundker C, Gunthert AR, Millar RP, Emons G. Expression of gonadotropin-releasing hormone II (GnRH-II) receptor in human endometrial and ovarian cancer cells and effects of GnRH-II on tumor cell proliferation. J Clin Endocrinol Metab 2002, 87:1427-1430. 10.1210/jc.87.3.1427, 11889221.
23. Emons G, Schroder B, Ortmann O, Westphalen S, Schulz KD, Schally AV. High affinity binding and direct antiproliferative effects of luteinizing hormone-releasing hormone analogs in human endometrial cancer cell lines. J Clin Endocrinol Metab 1993, 77:1458-1464. 10.1210/jc.77.6.1458, 8263128.
24. Sealfon SC, Weinstein H, Millar RP. Molecular mechanisms of ligand interaction with the gonadotropin-releasing hormone receptor. Endocr Rev 1997, 18:180-205. 10.1210/er.18.2.180, 9101136.
25. Emons G, Ortmann O, Becker M, Irmer G, Springer B, Laun R, Holzel F, Schulz KD, Schally AV. High affinity binding and direct antiproliferative effects of LHRH analogues in human ovarian cancer cell lines. Cancer Res 1993, 53:5439-5446.
26. Yano T, Pinski J, Halmos G, Szepeshazi K, Groot K, Schally AV. Inhibition of growth of OV-1063 human epithelial ovarian cancer xenografts in nude mice by treatment with luteinizing hormone-releasing hormone antagonist SB-75. Proc Natl Acad Sci USA 1994, 91:7090-7094. 10.1073/pnas.91.15.7090, 44344, 7518926.
27. Kang SK, Cheng KW, Nathwani PS, Choi KC, Leung PC. Autocrine role of gonadotropin-releasing hormone and its receptor in ovarian cancer cell growth. Endocrine 2000, 13:297-304. 10.1385/ENDO:13:3:297, 11216641.
28. Grundker C, Gunthert AR, Hellriegel M, Emons G. Gonadotropin-releasing hormone (GnRH) agonist triptorelin inhibits estradiol-induced serum response element (SRE) activation and c-fos expression in human endometrial, ovarian and breast cancer cells. Eur J Endocrinol 2004, 151:619-628. 10.1530/eje.0.1510619, 15538941.
29. Morgan K, Stewart AJ, Miller N, Mullen P, Muir M, Dodds M, Medda F, Harrison D, Langdon S, Millar RP. Gonadotropin-releasing hormone receptor levels and cell context affect tumor cell responses to agonist in vitro and in vivo. Cancer Res 2008, 68:6331-6340. 10.1158/0008-5472.CAN-08-0197, 18676858.
30. Pawson AJ, Maudsley S, Morgan K, Davidson L, Naor Z, Millar RP. Inhibition of human type i gonadotropin-releasing hormone receptor (GnRHR) function by expression of a human type II GnRHR gene fragment. Endocrinology 2005, 146:2639-2649. 10.1210/en.2005-0133, 15761034.
31. Kim KY, Choi KC, Auersperg N, Leung PC. Mechanism of gonadotropin-releasing hormone (GnRH)-I and -II-induced cell growth inhibition in ovarian cancer cells: role of the GnRH-I receptor and protein kinase C pathway. Endocr Relat Cancer 2006, 13:211-220. 10.1677/erc.1.01033, 16601289.
32. Engel J, Emons G, Pinski J, Schally AV. AEZS-108: a targeted cytotoxic analog of LHRH for the treatment of cancers positive for LHRH receptors. Expert Opin Investig Drugs 2012, 21:891-899. 10.1517/13543784.2012.685128, 22577891.
33. Naor Z, Benard O, Seger R. Activation of MAPK cascades by G-protein-coupled receptors: the case of gonadotropin-releasing hormone receptor. Trends Endocrinol Metab 2000, 11:91-99. 10.1016/S1043-2760(99)00232-5, 10707049.
34. Millar R, Lowe S, Conklin D, Pawson A, Maudsley S, Troskie B, Ott T, Millar M, Lincoln G, Sellar R, et al. A novel mammalian receptor for the evolutionarily conserved type II GnRH. Proc Natl Acad Sci USA 2001, 98:9636-9641. 10.1073/pnas.141048498, 55504, 11493674.
35. Moser TL, Young TN, Rodriguez GC, Pizzo SV, Bast RC, Stack MS. Secretion of extracellular matrix-degrading proteinases is increased in epithelial ovarian carcinoma. Int J Cancer 1994, 56:552-559. 10.1002/ijc.2910560415, 8112891.
36. Davidson B, Goldberg I, Gotlieb WH, Kopolovic J, Ben-Baruch G, Nesland JM, Reich R. The prognostic value of metalloproteinases and angiogenic factors in ovarian carcinoma. Mol Cell Endocrinol 2002, 187:39-45. 10.1016/S0303-7207(01)00709-2, 11988310.
37. Jedryka M, Chrobak A, Chelmonska-Soyta A, Gawron D, Halbersztadt A, Wojnar A, Kornafel J. Matrix metalloproteinase (MMP)-2 and MMP-9 Expression in Tumor Infiltrating CD3 Lymphocytes From Women With Endometrial Cancer. Int J Gynecol Cancer 2012, 22:1303-1309. 10.1097/IGC.0b013e318269e27b, 22964525.
38. Monge M, Colas E, Doll A, Gonzalez M, Gil-Moreno A, Planaguma J, Quiles M, Arbos MA, Garcia A, Castellvi J, et al. ERM/ETV5 up-regulation plays a role during myometrial infiltration through matrix metalloproteinase-2 activation in endometrial cancer. Cancer Res 2007, 67:6753-6759. 10.1158/0008-5472.CAN-06-4487, 17638886.
39. Sanceau J, Truchet S, Bauvois B. Matrix metalloproteinase-9 silencing by RNA interference triggers the migratory-adhesive switch in Ewing's sarcoma cells. J Biol Chem 2003, 278:36537-36546. 10.1074/jbc.M304300200, 12847101.
40. Nishida M, Kasahara K, Kaneko M, Iwasaki H, Hayashi K. Establishment of a new human endometrial adenocarcinoma cell line, Ishikawa cells, containing estrogen and progesterone receptors. Nippon Sanka Fujinka Gakkai Zasshi 1985, 37:1103-1111.
41. Mo B, Vendrov AE, Palomino WA, DuPont BR, Apparao KB, Lessey BA. ECC-1 cells: a well-differentiated steroid-responsive endometrial cell line with characteristics of luminal epithelium. Biol Reprod 2006, 75:387-394. 10.1095/biolreprod.106.051870, 16707768.
42. Chao A, Wang TH, Lee YS, Hsueh S, Chao AS, Chang TC, Kung WH, Huang SL, Chao FY, Wei ML, Lai CH. Molecular characterization of adenocarcinoma and squamous carcinoma of the uterine cervix using microarray analysis of gene expression. Int J Cancer 2006, 119:91-98. 10.1002/ijc.21813, 16450401.